Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dalfampridine Clear all
Completed Not applicable Interventional Results available

Dalfampridine and Gait in Spinocerebellar Ataxias

NCT01811706
View directory record Official record
Conditions
Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 18, 2026, 4:58 AM EDT
Recruiting Phase 2 Interventional

4-Aminopyridine to Treat Skin Burns

NCT06596434
View directory record Official record
Conditions
Burns, Second Degree Burn, Wounds and Injuries
Interventions
Drug: 4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 18, 2026, 4:58 AM EDT
Recruiting Phase 3 Interventional

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

NCT06136728
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy
Drug · Behavioral · Other
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
25 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 18, 2026, 4:58 AM EDT
Withdrawn Phase 2 Interventional

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

NCT03658408
View directory record Official record
Conditions
Prostate Disease
Interventions
4-aminopyridine, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

NCT01377922
View directory record Official record
Conditions
Lambert Eaton Myasthenic Syndrome
Interventions
Amifampridine Phosphate, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00654927
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR b.i.d. (Twice Daily)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

NCT02166346
View directory record Official record
Conditions
Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 18, 2026, 4:58 AM EDT
Completed No phase listed Observational Results available

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

NCT01535664
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Withdrawal of dalfampridine-ER 10mg
Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

NCT01645787
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
4-aminopyridine, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 18, 2026, 4:58 AM EDT
Approved For Marketing No phase listed Expanded access

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome
Interventions
3,4-DIAMINOPYRIDINE
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066
View directory record Official record
Conditions
Myasthenic Syndromes, Congenital
Interventions
amifampridine phosphate, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 18, 2026, 4:58 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

4-aminopyridine for Skin Wound Healing

NCT06333171
View directory record Official record
Conditions
Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT01683838
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 18, 2026, 4:58 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

NCT02422940
View directory record Official record
Conditions
Post-ischemic Stroke
Interventions
dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
62
States / cities
Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

NCT01491022
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ampyra first, then Placebo, placebo first, then Ampyra
Drug
Lead sponsor
University of Miami
Other
Eligibility
45 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 18, 2026, 4:58 AM EDT
Recruiting Phase 1 Interventional

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT07171203
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

NCT02656160
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Placebo, Dalfampridine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

NCT02271217
View directory record Official record
Conditions
Post-Ischemic Stroke
Interventions
Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
70
States / cities
Gilbert, Arizona • Berkeley, California • Long Beach, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 18, 2026, 4:58 AM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354
View directory record Official record
Conditions
Vestibular Migraine, Migraine Disorders, Vestibular Diseases
Interventions
4-aminopyridine, Atenolol, Placebo
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 18, 2026, 4:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma

NCT04026568
View directory record Official record
Conditions
Nerve Injury
Interventions
4-Aminopyridine, Placebo oral tablet
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 18, 2026, 4:58 AM EDT
No Longer Available No phase listed Expanded access

Treatment Use of 3,4-Diaminopyridine

NCT01765140
View directory record Official record
Conditions
Myasthenic Syndromes, Congenital
Interventions
3,4-diaminopyridine
Drug
Lead sponsor
Vern C. Juel, M.D.
Other
Eligibility
Not listed
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Dalfampridine/Placebo, Placebo/Dalfampridine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 18, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine

NCT00056810
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
4-aminopyridine (4-AP)
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 18, 2026, 4:58 AM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine in Episodic Ataxia Type 2

NCT01543750
View directory record Official record
Conditions
Episodic Ataxia Type 2
Interventions
4-Aminopyridine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 18, 2026, 4:58 AM EDT